Building a viable commercial model for cell and gene therapy
10 Feb 2026
Theatre 4
Commercial strategy and global access
Cell and gene therapy companies face unique challenges in achieving commercial sustainability, from manufacturing complexity to pricing and access. This session brings together perspectives from science, industry, and finance to examine the frameworks shaping viable business models in CGT and the strategies enabling success across the product lifecycle.
Key takeaways
- Examine how cost structures and reimbursement models influence CGT commercialization.
- Identify strategies for scaling manufacturing and supply chains efficiently.
- Discuss approaches to balance patient access with return on investment.
- Explore investor perspectives on risk, valuation, and long-term sustainability in CGT.
- Learn from cross-sector insights on building commercially and clinically viable therapies.
